Biotheranostics, Inc.
Records under this name other than the patents Biotheranostics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,447,470 | Tumor Grading and Cancer Prognosis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,021,754 | Tumor Grading and Cancer Prognosis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 12,492,432 | Tumor Grading and Cancer Prognosis Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,430,544 | Identification of Tumors and Tissues Lapsed on the fee record Ended Aug 30, 2026 · High confidence | Lapsed on the fee record | Ended Aug 30, 2026 | High confidence |
| US 9,670,553 | Determining Tumor Origin Term ended Term ended Jun 3, 2025 · Medium confidence | Term ended | Term ended Jun 3, 2025 | Medium confidence |
| US 10,538,816 | Identification of Tumors Term ended Term ended Jun 3, 2025 · High confidence | Term ended | Term ended Jun 3, 2025 | High confidence |
| US 7,504,214 | Predicting Outcome with Tamoxifen in Breast Cancer Term ended Term ended Feb 12, 2025 · High confidence | Term ended | Term ended Feb 12, 2025 | High confidence |
| US 7,930,105 | Grading of Breast Cancer Term ended Term ended May 6, 2023 · Medium confidence | Term ended | Term ended May 6, 2023 | Medium confidence |
| US 7,364,846 | Gene Expression Profiling from Ffpe Samples Formerly held Term ended Term ended Dec 27, 2022 · High confidence | Term ended | Term ended Dec 27, 2022 | High confidence |
| US 7,723,039 | Gene Expression Profiling from Ffpe Samples Formerly held Term ended Term ended Dec 23, 2022 · High confidence | Term ended | Term ended Dec 23, 2022 | High confidence |